Live vaccines for human metapneumovirus designed by reverse genetics

Expert Review of Vaccines

Volumn 5, Issue 5, 2006, Pages 695-706

  Buchholz, Ursula J ^a   Nagashima, Kunio ^b   Murphy, Brian R ^a   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Human metapneumovirus; Immunity; Live attenuated vaccine; Paramyxovirus; Pneumovirus; Protective antigens; Vaccine

Indexed keywords

GLYCINE DEHYDROGENASE (DECARBOXYLATING); HUMAN METAPNEUMOVIRUS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PALIVIZUMAB; PARAINFLUENZA VACCINE; PROTEIN M2; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN EXPRESSION; AVIAN PNEUMOVIRUS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFLUENZA; NONHUMAN; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA SYNTHESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPREGULATION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; CHILD, PRESCHOOL; CROSS REACTIONS; DRUG DESIGN; GENE DELETION; GENETIC VECTORS; GENOME, VIRAL; GLYCOPROTEINS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; METAPNEUMOVIRUS; MUTATION; PARAMYXOVIRIDAE INFECTIONS; RECOMBINATION, GENETIC; SEROTYPING; VACCINATION; VACCINES, ATTENUATED; VARIATION (GENETICS); VIRAL PROTEINS; VIRAL VACCINES;

EID: 33845864171     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.5.695     Document Type: Review

References (92)

1. van den Hoogen BG, de Jong JC, Groen J et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7(6), 719-724 (2001).
2. •• First description of human metapneumovirus (HMPV).
3. Crowe JE Jr. Human metapneumovirus as a major cause of human respiratory tract disease. Pediatr. Infect. Dis. J. 23(11 Suppl.), S215-S221 (2004).
4. Williams JV, Harris PA, Tollefson SJ et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350(5), 443-450 (2004).
5. •• Reviews the clinical disease caused by HMPV in infants.
6. Bastien N, Ward D, Van Caeseele P et al. Human metapneumovirus infection in the Canadian population. J. Clin. Microbiol. 41(10), 4642-4646 (2003).
7. Ebihara T, Endo R, Kikuta H et al. Human metapneumovirus infection in Japanese children. J. Clin. Microbiol. 42(1), 126-132 (2004).
8. Mackay IM, Bialasiewicz S, Waliuzzaman Z et al. Use of the P gene to genotype human metapneumovirus identifies 4 viral subtypes. J. Infect. Dis. 190(11), 1913-1918 (2004).
9. Madhi SA, Ludewick H, Abed Y, Klugman KP, Boivin G. Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants. Clin. Infect. Dis. 37(12), 1705-1710 (2003).
10. Hamelin ME, Abed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin. Infect. Dis. 38(7), 983-990 (2004).
11. • Reviews HMPV epidemiology.
12. Peret TC, Boivin G, Li Y et al. Characterization of human metapneumoviruses isolated from patients in North America. J. Infect. Dis. 185(11), 1660-1663 (2002).
13. Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg. Infect. Dis. 8(9), 897-901 (2002).
14. Biacchesi S, Skiadopoulos MH, Boivin G et al. Genetic diversity between human metapneumovirus subgroups. Virology 315(1), 1-9 (2003).
15. •• First complete genomic sequences of HMPV.
16. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 295(1), 119-132 (2002).
17. • HMPV genomic sequences.
18. Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, Buchholz UJ. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 321(2), 247-259 (2004).
19. •• HMPV reverse genetics system that is used for the generation of vaccine candidates.
20. Herfst S, de Graaf M, Schickli JH et al. Recovery of human metapneumovirus genetic lineages A and B from cloned cDNA. J. Virol. 78(15), 8264-8270 (2004).
21. • HMPV reverse genetics system.
22. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippinott, Williams and Wilkins, PA, USA 1443-1485 (2001).
23. Buchholz UJ, Biacchesi S, Pham QN et al. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J. Virol. 79(11), 6588-6597 (2005).
24. Biacchesi S, Skiadopoulos MH, Yang L et al. Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J. Virol. 78(23), 12877-12887 (2004).
25. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin-independent does not increase replication or spread in rodents or nonhuman primates. J. Virol. 80(12), 5798-5806 (2006).
26. Schickli JH, Kaur J, Ulbrandt N, Spaete RR, Tang RS. An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in vero cells and does not alter tissue tropism in hamsters. J. Virol. 79(16), 10678-10689 (2005).
27. Skiadopoulos MH, Biacchesi S, Buchholz UJ et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 345(2), 492-501 (2006).
28. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. The immunologic response to infection with respiratory syncytial virus in infants. J. Infect. Dis. 138(1), 24-32 (1978).
29. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13(11), 1006-1012 (1995).
30. Watt PJ, Robinson BS, Pringle CR, Tyrrell DA. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8(3), 231-236 (1990).
31. Murphy B. Mucosal immunity to viruses. In: Mucosal Immunology. Mestecky J (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands 799-814 (2005).
32. Tao T, Davoodi F, Cho CJ et al. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18(14), 1359-1366 (2000).
33. Kulkarni AB, Collins PL, Bacik I et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol. 69(2), 1261-1264 (1995).
34. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55(3), 517-520 (1985).
35. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 60(1), 51-59 (2003).
36. Bastien N, Normand S, Taylor T et al. Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Res. 93(1), 51-62 (2003).
37. Peret TC, Abed Y, Anderson LJ, Erdman DD, Boivin G. Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. J. Gen. Virol. 85(Pt 3), 679-686 (2004).
38. Bastien N, Liu L, Ward D, Taylor T, Li Y. Genetic variability of the G glycoprotein gene of human metapneumovirus. J. Clin. Microbiol. 42(8), 3532-3537 (2004).
39. Ishiguro N, Ebihara T, Endo R et al. High genetic diversity of the attachment (G) protein of human metapneumovirus. J. Clin. Microbiol. 42(8), 3406-3414 (2004).
40. Kaida A, Iritani N, Kubo H, Shiomi M, Kohdera U, Murakami T. Seasonal distribution and phylogenetic analysis of human metapneumovirus among children in Osaka City, Japan. J. Clin. Virol. 35(4), 394-399 (2006).
41. Agapov E, Sumino KC, Gaudreault-Keener M, Storch GA, Holtzman MJ. Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness. J. Infect. Dis. 193(3), 396-403 (2006).
42. Winther TN, Madsen CD, Pedersen AG, von Linstow ML, Eugen-Olsen J, Hogh B. Limited inter- and intra-patient sequence diversity of the genetic lineage A human metapneumovirus fusion gene. Virus Genes 31(1), 89-97 (2005).
43. van den Hoogen BG, Herfst S, Sprong L et al. Antigenic and genetic variability of human metapneumoviruses. Emerg. Infect. Dis. 10(4), 658-666 (2004).
44. Skiadopoulos MH, Biacchesi S, Buchholz UJ et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J. Virol. 78(13), 6927-6937 (2004).
45. MacPhail M, Schickli JH, Tang RS et al. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J. Gen. Virol. 85(Pt 6), 1655-1663 (2004).
46. Kuiken T, van den Hoogen BG, van Riel DA et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am. J. Pathol. 164(6), 1893-1900 (2004).
47. Mullins JA, Erdman DD, Weinberg GA et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg. Infect. Dis. 10(4), 700-705 (2004).
48. van den Hoogen BG, Osterhaus DM, Fouchier RA. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr. Infect. Dis. J. 23(1 Suppl.), S25-S32 (2004).
49. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J. Infect. Dis. 187(5), 785-790 (2003).
50. Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin. Infect. Dis. 42(4), 518-524 (2006).
51. Moss WJ, Polack FP. Immune responses to measles and measles vaccine: challenges for measles control. Viral Immunol. 14(4), 297-309 (2001).
52. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4), 405-421 (1969).
53. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
54. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103(1-2), 177-185 (2004).
55. Jefferson T, Smith S, Demicheli V,
56. Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365(9461), 773-780 (2005).
57. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. 110(1), 21-27 (2002).
58. Olszewska W, Helson R, Openshaw PJ. Vaccines for the prevention of respiratory viral infections: problems and current status. Exp.Opin. Investig. Drugs 13(6), 681-689 (2004).
59. Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin. Infect. Dis. 33(10), 1720-1727 (2001).
60. Karron RA, Belshe RB, Wright PF et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22(5), 394-405 (2003).
61. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med. 196(10), 1381-1386 (2002).
62. Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191(7), 1093-1104 (2005).
63. Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5), 1331-1342 (2000).
64. Karron RA, Wright PF, Crowe JE Jr et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176(6), 1428-1436 (1997).
65. Collins PL, Whitehead SS, Bukreyev A et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. 54, 423-451 (1999).
66. Crowe JE Jr, Firestone CY, Whitehead SS, Collins PL, Murphy BR. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13(3), 269-273 (1996).
67. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72(5), 4467-4471 (1998).
68. Collins PL, Murphy BR. Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296(2), 204-211 (2002).
69. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J. Virol. 79(19), 12608-12613 (2005).
70. • Characterization of HMPV vaccine candidates in nonhuman primates.
71. Kochva U, Leonov H, Arkin IT. Modeling the structure of the respiratory syncytial virus small hydrophobic protein by silentmutation analysis of global searching molecular dynamics. Protein Sci. 12(12), 2668-2674 (2003).
72. Perez M, Garcia-Barreno B, Melero JA, Carrasco L, Guinea R. Membrane permeability changes induced in Escherichia coli by the SH protein of human respiratory syncytial virus. Virology 235(2), 342-351 (1997).
73. Karron RA, Buonagurio DA, Georgiu AF et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA 94(25), 13961-13966 (1997).
74. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289(2), 283-296 (2001).
75. Collins PL, Camargo E, Hill MG. Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus. Virology 259(2), 251-255 (1999).
76. Collins PL, Hill MG, Cristina J, Grosfeld H. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc. Natl Acad. Sci. USA 93(1), 81-85 (1996).
77. Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J. Virol. 73(7), 5852-5864 (1999).
78. Pham QN, Biacchesi S, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J. Virol. 79(24), 15114-15122 (2005).
79. • Phenotypic analysis of a HMPV vaccine candidate that is being prepared currently for clinical trials.
80. Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24(14), 2674-2684 (2006).
81. McAuliffe JM, Surman SR, Newman JT et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J. Virol. 78(4), 2029-2036 (2004).
82. Nolan SM, Surman SR, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoulos MH. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 23(39), 4765-4774 (2005).
83. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75(10), 4594-4603 (2001).
84. Williams JV, Tollefson SJ, Johnson JE, Crowe JE Jr. The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J. Virol. 79(17), 10944-10951 (2005).
85. Wyde PR, Chetty SN, Jewell AM, Schoonover SL, Piedra PA. Development of a cotton rat-human metapneumovirus (hMPV) model for identifying and evaluating potential hMPV antivirals and vaccines. Antiviral Res. 66(1), 57-66 (2005).
86. Hamelin ME, Yim K, Kuhn KH et al. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J. Virol. 79(14), 8894-8903 (2005).
87. Piedra PA, Cron SG, Jewell A et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21(19-20), 2448-2460 (2003).
88. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob. Agents Chemother. 50(2), 774-777 (2006).
89. Ma X, Endo R, Ebihara T, Ishiguro N, Ishiko H, Kikuta H. Production and characterization of neutralizing monoclonal antibodies against human metapneumovirus F protein. Hybridoma (Larchmt) 24(4), 201-205 (2005).
90. Ditzel HJ, Parren PW, Binley JM et al. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267(3), 684-695 (1997).
91. Website
92. American College of Emergency Physicians www.acep.org/webportal/ MemberCenter/Periodicals/Medical+News/infectiousdiseases/default.htm?newsid= 0c023ab2